Co-Authors
This is a "connection" page, showing publications co-authored by ALAN SWANN and BRITTANY O'BRIEN.
Connection Strength
1.771
-
Anti-suicidal effects of IV ketamine in a real-world setting. Psychiatry Res. 2024 Jan; 331:115604.
Score: 0.233
-
Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
Score: 0.216
-
Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 05 01; 286:320-329.
Score: 0.193
-
Impulsivity and Suicidal Behavior. Curr Top Behav Neurosci. 2020; 47:179-195.
Score: 0.178
-
Psychotherapy for Mixed Depression and Mixed Mania. Psychiatr Clin North Am. 2020 03; 43(1):199-211.
Score: 0.177
-
The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression. Pharmaceuticals (Basel). 2019 Sep 11; 12(3).
Score: 0.174
-
Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression. Contemp Clin Trials Commun. 2019 12; 16:100432.
Score: 0.173
-
Interactions of immediate and long-term action regulation in the course and complications of bipolar disorder. Philos Trans R Soc Lond B Biol Sci. 2019 02 18; 374(1766):20180132.
Score: 0.168
-
Correction: Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 Oct; 48(11):1699.
Score: 0.058
-
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593.
Score: 0.056
-
Does mismatch negativity have utility for NMDA receptor drug development in depression? Braz J Psychiatry. 2022 Jan-Feb; 44(1):61-73.
Score: 0.051
-
Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2021 11; 38(11):1108-1119.
Score: 0.049
-
A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSD. Front Psychiatry. 2019; 10:846.
Score: 0.044